Antibody association with HER-2/neu-targeted vaccine enhances CD8 + T cell responses in mice through Fc-mediated activation of DCs

Journal of Clinical Investigation

Volumn 118, Issue 5, 2008, Pages 1700-1711

  Kim, Peter S ^a,b   Armstrong, Todd D ^a,b   Song, Hong ^a,b   Wolpoe, Matthew E ^a,b   Weiss, Vivian ^a,b   Manning, Elizabeth A ^a,b   Huang, Lan Qing ^a,b   Murata, Satoshi ^a,b   Sgouros, George ^a,b   Emens, Leisha A ^a,b   Reilly, R Todd ^a,b   Jaffee, Elizabeth M ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 7.16.4; TUMOR ANTIGEN; TUMOR VACCINE;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELLULAR IMMUNITY; COMBINATION CHEMOTHERAPY; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG POTENTIATION; DRUG TARGETING; FEMALE; IMMUNOTHERAPY; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TRANSGENICS; VACCINATION;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD11C; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; DENDRITIC CELLS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNOGLOBULIN FC FRAGMENTS; MICE; MICE, TRANSGENIC; NEOPLASMS; RECEPTOR, ERBB-2; SURVIVAL RATE;

EID: 43049144967     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI34333     Document Type: Article

References (49)

1. Gallegos, A.M., and Bevan, M.J. 2006. Central tolerance: good but imperfect. Immunol. Rev. 209:290-296.
2. Li, L., and Boussiotis, V.A. 2006. Physiologic regulation of central and peripheral T cell tolerance: lessons for therapeutic applications. J. Mol. Med. 84:887-899.
3. Piccirillo, C.A., and Shevach, E.M. 2004. Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin. Immunol. 16:81-88.
4. Wang, H.Y., and Wang, R.F. 2007. Regulatory T cells and cancer. Curr. Opin. Immunol. 19:217-223.
5. Drake, C.G., Jaffee, E., and Pardoll, D.M. 2006. Mechanism of immune evasion by tumors. Adv. Immunol. 90:51-81.
6. Gajewski, T.F., et al. 2006. Immune resistance orchestrated by the tumor microenvironment. Immunol. Rev. 213:131-145.
7. Emens, L.A., and Jaffee, E.M. 2005. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res. 65:8059-8064.
8. Kim, R., Emi, M., and Tanabe, K. 2005. Cancer cells immune escape and tumor progression by exploitation of anti-inflammatory and pro-inflammatory responses. Cancer Biol. Ther. 4:924-933.
9. + T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J. Immunol. 172:989-999.
10. Kusmartsev, S., and Gabrilovich, D.I. 2006. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol. Immunother. 55:237-245.
11. Balkwill, F., Charles, K.A., and Mantovani, A. 2005. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 7:211-217.
12. Laheru, D.A., Pardoll, D.M., and Jaffee, E.M. 2005. Genes to vaccines for immunotherapy: how the molecular biology revolution has influenced cancer immunology. Mol. Cancer Ther. 4:1645-1652.
13. Dranoff, G., et al. 1993. Vaccination with irradiated tumor cells engineered to secrete murine GM-CSF stimulates potent, specific, long lasting antitumor immunity. Proc. Natl. Acad. Sci. U. S. A. 90:3539-3543.
14. O'Mahony, D., and Bishop, M.R. 2006. Monoclonal antibody therapy. Front. Biosci. 11:1620-1635.
15. Mohsin, S.K., et al. 2005. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J. Clin. Oncol. 23:2460-2468.
16. Clynes, R.A., Towers, T.L., Presta, L.G., and Ravetch, J.V. 2000. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6:443-446.
17. Cartron, G., et al. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 99:754-758.
18. Weng, W.K., and Levy, R. 2003. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21:3940-3947.
19. Romani, L., et al. 2004. The exploitation of distinct recognition receptors in dendritic cells determines the full range of host immune relationships with Candida albicans. Int. Immunol. 16:149-161.
20. Shaw, D.R., and Griffin, F.M., Jr. 1981. Phagocytosis requires repeated triggering of macrophage phagocytic receptors during particle ingestion. Nature. 289:409-411.
21. Dhodapkar, K.M., et al. 2005. Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody coated tumor cells. Proc. Natl. Acad. Sci. U. S. A. 102:2910-2915.
22. Kalergis, A.M., and Ravetch, J.V. 2002. Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J. Exp. Med. 195:1653-1659.
23. Mach, P., Serre, K., and Leserman, L. 2000. Class I-restricted presentation of exogenous antigen acquired by Fcgamma receptor-mediated endocytosis is regulated in dendritic cells. Eur. J. Immunol. 30:848-857.
24. Yada, A., et al. 2003. Accelerated antigen presentation and elicitation of humoral response in vivo by FcgammaRIIB- and FcgammaRI/III-mediated immune complex uptake. Cell Immunol. 225:21-32.
25. Regnault, A., et al. 1999. Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J. Exp. Med. 189:371-380.
26. + cytotoxic T cells. Leukemia. 15:1619-1626.
27. + T cell effector function and tumor-free survival in Her-2/neu-transgenic mice. J. Immunol. 171:2161-2169.
28. + CTL responses in vivo. J. Immunol. 168:2240-2246.
29. Schuurhuis, D.H., et al. 2006. Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine. J. Immunol. 176:4573-4580.
30. Dhodapkar, K.M., Krasovsky, J., Williamson, B., and Dhodapkar, M.V. 2002. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J. Exp. Med. 195:125-133.
31. Rafiq, K., Bergtold, A., and Clynes, R. 2002. Immune complex-mediated antigen presentation induces tumor immunity. J. Clin. Invest. 110:71-79.
32. Ercolini, A.M., et al. 2003. Identification and characterization of the immunodominant rat HER-2 MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice. J. Immunol. 170:4273-4280.
33. Manning, E.A., et al. 2007. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin. Cancer Res. 13:3951-3959.
34. - dendritic cells in vivo. J. Exp. Med. 196:817-827.
35. Dudziak, D., et al. 2007. Differential antigen processing by dendritic cell subsets in vivo. Science. 315:107-111.
36. Burgdorf, S., Kautz, A., Bohnert, V., Knolle, P.A., and Kurtis, C. 2007. Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science. 316:612-616.
37. Akiyama, K., et al. 2003. Targeting apoptotic tumor cells to FcγR provides efficient and versatile vaccination against tumors by dendritic cells. J. Immunol. 170:1641-1648.
38. Winkel, K., Sotzik, F., Vremec, D., Cameron, P.U., and Shortman, K. 1994. CD4 and CD8 expression by human and mouse thymic dendritic cells. Immunol. Lett. 40:93-99.
39. Sallusto, F., Geginat, J., and Lanzavecchia, A. 2004. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22:745-763.
40. Bonasio, R., and von Andrian, U.H. 2006. Generation, migration and function of circulating dendritic cells. Curr. Opin. Immunol. 18:503-511.
41. Belyakov, I.M., Hammond, S.A., Ahlers, J.D., Glenn, G.M., and Berzofsky, J.A. 2004. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J. Clin. Invest. 113:998-1007.
42. Enioutina, E.Y., Visic, D., and Daynes, R.A. 2000. The induction of systemic and mucosal immune responses to antigen-adjuvant compositions administered into the skin: alterations in the migratory properties of dendritic cells appears to be important for stimulating mucosal immunity. Vaccine. 18:2753-2767.
43. Mimura, K., et al. 2005. Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma. Clin. Cancer Res. 11:4898-4904.
44. Guy, C.T., et al. 1992. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. U. S. A. 89:10578-10582.
45. Machiels, J.P., et al. 2001. Cyclophosmide, doxorubicin, and paclitaxel enhance the antitumor response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. 61:3869-3697.
46. Reilly, R.T., et al. 2000. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res. 60:3569-3576.
47. Reilly, R.T., et al. 2001. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res. 61:880-883.
48. Brechbiel, M.W., et al. 1991. An effective chelating agent for labeling of monoclonal antibody with Bi-212 for a-particle mediated radioimmunotherapy. J. Chem. Soc. Chem. Commun. 1169-1170.
49. Nikula, T.K., et al. 1995. A rapid, single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodies. Nucl. Med. Biol. 22:387-390.